Opportunity Information: Apply for RFA HL 12 034
Apply for RFA HL 12 034
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Management of HIV Related Lung Disease and Cardiovascular Co Morbidity (R34)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.838 Lung Diseases Research.
- This funding opportunity was created on Nov 17, 2011 and posted on Nov 17, 2011.
- Applicants must submit their applications by Mar 15, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $400,000.00 in funding.
- Eligible applicants include: Private institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) State governments Special district governments Independent school districts County governments Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses City or township governments Native American tribal governments (Federally recognized).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Management of HIV Related Lung Disease and Cardiovascular Co-Morbidity (R34) funding opportunity (RFA-HL-12-034) is a National Institutes of Health discretionary grant announcement designed to help research teams get ready to run larger, later-stage clinical trials in people living with HIV who have lung disease, either by itself or alongside cardiovascular disease. The award mechanism is an R34 clinical trial planning grant, which means it is not primarily meant to fund a full Phase II or Phase III trial. Instead, it supports the early, practical work that has to happen before a robust trial can realistically launch, including building the trial infrastructure, developing and refining the study protocol, and completing targeted preliminary studies that reduce uncertainty and strengthen the eventual trial design.
The scientific aim driving this opportunity is the need to improve how HIV-related lung disease is managed, especially when cardiovascular co-morbidity is also present, because these conditions can substantially increase illness and death in HIV-infected populations. The FOA is centered on planning clinical trials that test and optimize intervention strategies. In practice, that typically means sharpening questions like which interventions are most promising, what outcomes should be measured, how patients should be selected and stratified (for example, by disease severity or risk profile), and what operational approaches will make the trial feasible across sites and populations. The planning grant is intended to position investigators to move forward with strong Phase II and Phase III trials that can produce reliable, actionable evidence about how best to reduce morbidity and mortality tied to these pulmonary and cardiovascular complications in people with HIV.
From a funding and administrative standpoint, the opportunity is categorized under Health and linked to CFDA 93.838 (Lung Diseases Research). NIH indicated an estimated total funding amount of $2,000,000 for the announcement, with an award ceiling of $400,000, and there is no cost-sharing or matching requirement. The announcement was posted on November 17, 2011, with an original and current closing date of March 15, 2012, and an archive date of April 15, 2012. These dates place it as a time-limited solicitation during that period rather than an open-ended program.
Eligibility is broad and includes many types of U.S.-based organizations and governmental entities. Eligible applicants listed include public and private institutions of higher education, nonprofits both with and without 501(c)(3) status, small businesses, for-profit organizations other than small businesses, state and local governments (including counties, cities, townships, special district governments, and independent school districts), public housing authorities/Indian housing authorities, and Native American tribal governments and tribal organizations. The FOA also explicitly notes additional eligible applicant categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Alaska Native and Native Hawaiian Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), regional organizations, faith-based or community-based organizations, U.S. territories or possessions, and eligible federal agencies. Foreign institutions are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible, although foreign components (as NIH defines them in the NIH Grants Policy Statement) are allowed, which typically means certain collaborations or elements may be permissible if they meet NIH’s definition and policy requirements.
Operationally, the FOA points applicants to the full NIH announcement page for complete details, and it provides NIH Office of Extramural Research (OER) webmaster contacts for help accessing or linking to the funding announcement. Overall, this R34 opportunity is best understood as a focused planning-stage investment: it pays for the organizational and technical groundwork needed to design rigorous Phase II/III trials aimed at improving intervention strategies for HIV-related lung disease, including the added complexity of cardiovascular co-morbidity, with the ultimate goal of reducing serious health outcomes in this population.
Frequently Asked Questions (FAQs)
What is the name of this funding opportunity?
The opportunity is titled "The Management of HIV Related Lung Disease and Cardiovascular Co-Morbidity (R34)" and is identified as RFA-HL-12-034.
Which agency is offering this grant?
This is a National Institutes of Health (NIH) discretionary grant announcement.
What is the purpose of this R34 funding opportunity?
The purpose is to support clinical trial planning activities that help research teams prepare to run larger, later-stage (Phase II and Phase III) clinical trials focused on improving management of HIV-related lung disease, including situations where cardiovascular co-morbidity is also present.
Is this grant meant to pay for a full Phase II or Phase III clinical trial?
No. This is an R34 clinical trial planning grant. It is not primarily intended to fund a full Phase II or Phase III trial. It supports the early, practical work needed before a robust trial can realistically launch.
What types of activities can this planning grant support?
Based on the description provided, the R34 supports planning-stage work such as building trial infrastructure, developing and refining the study protocol, and completing targeted preliminary studies designed to reduce uncertainty and strengthen the eventual trial design.
What health conditions are the focus of this opportunity?
The focus is on HIV-related lung disease and, in particular, the added complexity of cardiovascular co-morbidity when it occurs alongside lung disease in people living with HIV.
What is the scientific rationale for this FOA?
The opportunity is driven by the need to improve management of HIV-related lung disease, especially when cardiovascular co-morbidity is present, because these conditions can substantially increase illness and death in HIV-infected populations.
What kind of research is the FOA centered on?
The FOA is centered on planning clinical trials that test and optimize intervention strategies aimed at reducing morbidity and mortality tied to pulmonary and cardiovascular complications in people with HIV.
What kinds of trial-design questions is this planning grant intended to help address?
The planning work is described as helping investigators sharpen questions such as which interventions are most promising, what outcomes should be measured, how patients should be selected and stratified (for example, by disease severity or risk profile), and what operational approaches will make the trial feasible across sites and populations.
What is the award mechanism?
The award mechanism is an R34 clinical trial planning grant.
What is the estimated total funding amount for this announcement?
NIH indicated an estimated total funding amount of $2,000,000 for the announcement.
What is the maximum award amount (award ceiling)?
The award ceiling is $400,000.
Is cost-sharing or matching required?
No. The opportunity states that there is no cost-sharing or matching requirement.
What is the CFDA number associated with this opportunity?
The opportunity is linked to CFDA 93.838 (Lung Diseases Research).
How is this opportunity categorized?
It is categorized under Health.
When was the announcement posted?
The announcement was posted on November 17, 2011.
What is the application deadline?
The original and current closing date listed is March 15, 2012.
Is this opportunity still open?
No. The dates provided indicate it was a time-limited solicitation. The closing date was March 15, 2012, and the archive date was April 15, 2012.
What does the archive date indicate?
The archive date of April 15, 2012 indicates the announcement is from a past cycle and is not an open-ended, ongoing program based on the information provided.
Who is eligible to apply?
Eligibility is broad and includes many U.S.-based organizations and governmental entities, including public and private institutions of higher education; nonprofits with or without 501(c)(3) status; small businesses; for-profit organizations other than small businesses; and state and local governments (including counties, cities, townships, special district governments, and independent school districts).
Are public housing authorities eligible?
Yes. Public housing authorities/Indian housing authorities are listed as eligible applicants.
Are Native American tribal governments and tribal organizations eligible?
Yes. Native American tribal governments and tribal organizations are listed as eligible.
Are minority-serving institutions specifically included as eligible applicants?
Yes. The FOA explicitly notes eligibility for categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Alaska Native and Native Hawaiian Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), and other listed categories.
Are faith-based or community-based organizations eligible?
Yes. Faith-based or community-based organizations are explicitly listed as eligible applicant categories.
Are U.S. territories or possessions eligible?
Yes. U.S. territories or possessions are listed among eligible applicant categories.
Are eligible federal agencies allowed to apply?
Yes. Eligible federal agencies are listed as eligible applicants.
Are foreign institutions eligible to apply?
No. Foreign institutions are not eligible to apply.
Are non-U.S. components of U.S. organizations eligible?
No. Non-U.S. components of U.S. organizations are also not eligible.
Are any foreign components allowed at all?
Yes. While foreign institutions cannot apply and non-U.S. components of U.S. organizations are not eligible, the FOA indicates that foreign components (as NIH defines them in the NIH Grants Policy Statement) are allowed, meaning certain collaborations or elements may be permissible if they fit NIH definitions and policy requirements.
Where should applicants go for complete details?
Applicants are directed to the full NIH announcement page for complete details.
Who can help with access or linking issues related to the announcement?
The FOA provides NIH Office of Extramural Research (OER) webmaster contacts for help accessing or linking to the funding announcement.
What is the overall takeaway for prospective applicants?
This R34 opportunity is best understood as a planning-stage investment that supports the organizational and technical groundwork needed to design rigorous Phase II/III trials aimed at improving intervention strategies for HIV-related lung disease, including cases complicated by cardiovascular co-morbidity, with the ultimate goal of reducing serious health outcomes in people with HIV.
Browse more opportunities from the same category: Health
Next opportunity: Rheumatic Diseases Research Core Centers (P30)
Previous opportunity: Plant Feedstock Genomics for Bioenergy A Joint Research Funding Opportunity Announcement USDA, DOE
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 12 034
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 12 034) also looked into and applied for these:
| Funding Opportunity |
|---|
| Rheumatic Diseases Research Core Centers (P30) Apply for RFA AR 12 002 Funding Number: RFA AR 12 002 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| Technology Development to Enable Large Scale Metabolomics Analyses (R01) Apply for RFA RM 11 019 Funding Number: RFA RM 11 019 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Scale Up of Care and Support Services for Orphans and Vulnerable Children (OVC) in Selected States in Nigeria Apply for RFA 620 11 012 Funding Number: RFA 620 11 012 Agency: Nigeria USAID Abuja Category: Health Funding Amount: $32,500,000 |
| Alcohol impairment of immune function, host defense and tissue homeostasis (R01) Apply for PA 12 025 Funding Number: PA 12 025 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alcohol impairment of immune function, host defense and tissue homeostasis (R21) Apply for PA 12 026 Funding Number: PA 12 026 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Effects of adolescent binge drinking on brain development (R01) Apply for PA 12 027 Funding Number: PA 12 027 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Effects of Adolescent Binge Drinking on Brain Development (R21) Apply for PA 12 028 Funding Number: PA 12 028 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Screening and Brief Alcohol Interventions in Underage and Young Adult Populations (R03) Apply for PA 12 029 Funding Number: PA 12 029 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Screening and Brief Alcohol Interventions in Underage and Young Adult Populations (R21) Apply for PA 12 030 Funding Number: PA 12 030 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Screening and Brief Alcohol Interventions in Underage and Young Adult Populations (R01) Apply for PA 12 031 Funding Number: PA 12 031 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| New Tools to Study Astrocyte Heterogeneity, Development and Function in Brain Regions Relevant to Mental Illness (R01) Apply for RFA MH 13 010 Funding Number: RFA MH 13 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mechanisms Mediating Osteoarthritis in Aging (R21) Apply for PA 12 018 Funding Number: PA 12 018 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Mechanisms Mediating Osteoarthritis in Aging (R01) Apply for PA 12 019 Funding Number: PA 12 019 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Translational Research in Alcoholic Hepatitis (U01) Apply for RFA AA 12 007 Funding Number: RFA AA 12 007 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Studies to evaluate cellular heterogeneity using transcriptional profiling of single cells (U01) Apply for RFA RM 11 013 Funding Number: RFA RM 11 013 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Exceptionally Innovative Tools and Technologies for Single Cell Analysis (R21) Apply for RFA RM 11 014 Funding Number: RFA RM 11 014 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Accelerating the Integration and Translation of Technologies to Characterize Biological Processes at the Single Cell Level (R01) Apply for RFA RM 11 015 Funding Number: RFA RM 11 015 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Stem/Progenitor Cell Derived Human Micro organs and tissues (U18) Apply for RFA RM 12 001 Funding Number: RFA RM 12 001 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Asthma and Allergic Diseases Cooperative Research Centers (U19) Apply for RFA AI 12 006 Funding Number: RFA AI 12 006 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Limited Competition Alzheimers Disease Cooperative Study (U19) Apply for RFA AG 13 001 Funding Number: RFA AG 13 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 12 034", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.